(SLN) Silence Therapeutics

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi




1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are Silence Therapeutics plc
attached:ii

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights YES

An acquisition or disposal of qualifying financial instruments which may
result in the acquisition of shares already issued to which voting rights
are attached

An acquisition or disposal of instruments with similar economic effect to
qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the Richard Bernstein (Pershing
notification obligation:iii Nominees and Hargreave Hale
Nominees)

4. Full name of shareholder(s) Pershing Nominees and
(if different from 3.):iv Hargreave Hale Nominees

5. Date of the transaction and date on
which the threshold is crossed or 23thJanuary 2012
reached: v

6. Date on which issuer notified: 25th January 2012

7. Threshold(s) that is/are crossed or 4%
reached: vi, vii





8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of Situation previous Resulting situation after the triggering transaction
shares to the triggering
transaction

if possible Number Number Number Number of voting % of voting rights
using of of of shares rights x
the ISIN CODE Shares Voting
Rights Direct Direct xi Indirect Direct Indirect
xii



GBP 1p ISIN:
18,440,000 3.20% 21,670,000 21,670,000 3.75%
GB0008433350






B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial Expiration Exercise/ Number of voting % of voting
instrument date xiii Conversion Period xiv rights that may be rights
acquired if the
instrument is
exercised/ converted.






C: Financial Instruments with similar economic effect to Qualifying Financial
Instruments xv, xvi

Resulting situation after the triggering transaction

Type of Exercise Expiration Exercise/ Number of voting rights % of voting
financial price date xvii Conversion instrument refers to rights xix, xx
instrument period xviii



CFD 4,185,000 Nominal Delta
(Spread
Bet)
0.73



Total (A+B+C)

Number of voting rights Percentage of voting rights

25,855,000 4.48%





9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi








Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease
to hold:

12. Date on which proxy holder will cease to hold
voting rights:





13. Additional information:

14. Contact name: Richard Bernstein

15. Contact telephone number: 020 7478 9070





Note: Annex should only be submitted to the FSA not the issuer




Annex: Notification of major interests in sharesxxii




A: Identity of the persons or legal entity subject to the notification
obligation

Full name

(including legal form of legal entities) Richard Bernstein



Contact address

(registered office for legal entities) 29 Curzon Street, London W1J 7TL



Phone number & email

020 7478 9070

Other useful information

(at least legal representative for legal persons)





B: Identity of the notifier, if applicable

Full name Richard Bernstein



Contact address

29 Curzon Street, London W1J 7TL

Phone number & email

020 7478 9070 -
richard.bernstein@eurovestech.com



Other useful information

(e.g. functional relationship with the person or legal
entity subject to the notification obligation)




C: Additional information



For notes on how to complete form TR-1 please see the FSA website.






END

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi



1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are Silence Therapeutics plc
attached:ii

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights YES

An acquisition or disposal of qualifying financial instruments which may
result in the acquisition of shares already issued to which voting rights
are attached

An acquisition or disposal of instruments with similar economic effect to
qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the Richard Bernstein (Pershing
notification obligation:iii Nominees and Hargreave Hale
Nominees)

4. Full name of shareholder(s) Pershing Nominees and
(if different from 3.):iv Hargreave Hale Nominees

5. Date of the transaction and date on
which the threshold is crossed or 18th January 2012
reached: v

6. Date on which issuer notified: 20th January 2012

7. Threshold(s) that is/are crossed or 3%
reached: vi, vii





8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type Situation previous Resulting situation after the triggering transaction
of to the triggering
shares transaction


if possible Number Number Number Number of voting % of voting rights x
using of of of shares rights
the ISIN Shares Voting
CODE Rights
Direct Direct xi Indirect xii Direct Indirect




GBP 1p ISIN:
<3% <3% 18,440,000 18,440,000 3.2%
GB0008433350





B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial Expiration Exercise/ Number of voting % of voting
instrument date xiii Conversion Period xiv rights that may be rights
acquired if the
instrument is
exercised/ converted.





C: Financial Instruments with similar economic effect to Qualifying Financial
Instruments xv, xvi

Resulting situation after the triggering transaction

Type of Exercise price Expiration Exercise/ Number of voting rights % of voting rights
financial date xvii Conversion period instrument refers to xix, xx
instrument xviii


CFD (Spread 4,185,000 Nominal Delta
Bet)
0.73



Total (A+B+C)

Number of voting rights Percentage of voting rights

22,625,000 3.92%





9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi







Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease
to hold:

12. Date on which proxy holder will cease to hold
voting rights:




13. Additional information:

14. Contact name: Richard Bernstein

15. Contact telephone number: 020 7478 9070





Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in sharesxxii



A: Identity of the persons or legal entity subject to the notification
obligation

Full name

(including legal form of legal entities) Richard Bernstein



Contact address

(registered office for legal entities) 29 Curzon Street, London W1J 7TL



Phone number & email

020 7478 9070

Other useful information

(at least legal representative for legal persons)





B: Identity of the notifier, if applicable

Full name Richard Bernstein



Contact address

29 Curzon Street, London W1J 7TL

Phone number & email

020 7478 9070 -
richard.bernstein@eurovestech.com



Other useful information

(e.g. functional relationship with the person or legal
entity subject to the notification obligation)



C: Additional information



For notes on how to complete form TR-1 please see the FSA website.






END

FOR IMMEDIATE RELEASE

Silence Therapeutics signs collaboration with miRagen Therapeutics to evaluate
delivery of novel microRNA-based therapeutics

-- Third collaboration to investigate the potential application of Silence's
proprietary RNAi delivery technologiesin the development of novel microR
NA-based therapeutics--

London, UK, January 9, 2011 - Silence Therapeutics plc (AIM: SLN) ("Silence"),
a leading RNA interference (RNAi) therapeutics company, announces that it has
signed an agreement with miRagen Therapeutics, Inc. ("miRagen"), to assess the
delivery potential of Silence's proprietary DBTC delivery system with miRagen's
novel microRNA- (miRNA-) based therapeutics. MiRagen is a pre-clinical stage
biopharmaceutical company founded to develop innovative miRNA-based
therapeutics for the treatment of cardiovascular and muscle disease.

Under the terms of the agreement, miRagen will provide Silence with specific
miRNA sequences, which Silence will formulate with its proprietary DBTC
delivery system in order to develop multiple candidate drugs. MiRagen will
undertake in vitro and in vivo studies of the candidate drugs developed under
the agreement and select lead candidates for further evaluation. Financial
terms of the collaboration are not disclosed.

DBTC is a proprietary RNAi delivery system developed by Silence. It is a novel
lipid-based formulation that functionally delivers short interfering RNA (
siRNA) to liver endothelial cells, hepatocytes and other liver cell types with
high efficiency.

Thomas Christély, Chief Executive Officer of Silence Therapeutics, said: "We
are delighted to be collaborating with miRagen. This is the third collaboration
that we have recently signed to explore the use of Silence's delivery
technologies for microRNAs, and the second that utilizes our novel DBTC
delivery system that specifically delivers RNAi therapeutics to the liver.
Whilst we remain internally focused on the delivery of our siRNA therapies, we
continue to broaden the potential value of our proprietary delivery systems by
collaborating with partners. Functional delivery to target cells is widely
recognized as one of the greatest challenges facing most nucleic acid
therapies. Our three proprietary RNAi delivery systems, AtuPLEX™, DACC and DBTC
deliver effective doses of RNAi to key intracellular targets in vascular
endothelium, lung and liver respectively, and provide our partners with a
growing range of solutions to overcome their delivery challenges."

William S. Marshall, President and Chief Executive Officer of miRagen
Therapeutics, said:"We are very pleased to have entered into this agreement
with Silence Therapeutics, which gives us the opportunity to evaluate the
efficacy of a promising delivery system in the context of microRNA
manipulation. This is another example of miRagen's commitment to explore the
potential of cutting-edge technologies with the ultimate goal of better serving
patients in need."

--Ends--

For further information, please contact:

Silence Therapeutics miRagen Therapeutics

Thomas Christély / Max Herrmann Tammy Egan
+49 30 9489 2800/+44 20 7491 6520 +1 720 407 4588
t.christely@silence-therapeutics.com tegan@miragenrx.com
m.herrmann@silence-therapeutics.com

Singer Capital Markets M:Communications

Shaun Dobson / Claes Spång Mary-Jane Elliott / Emma Thompson / Claire
Dickinson
+44 20 32057500 +44 20 7920 2345
shaun.dobson@singercm.com silencetherapeutics@mcomgroup.com
claes.spang@singercm.com

Notes for editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company
dedicated to the discovery, development and delivery of targeted, systemic RNA
interference (RNAi) therapeutics for the treatment of serious diseases. Silence
offers one of the most comprehensive short interfering RNA (siRNA) therapeutic
platforms available today based on a strong intellectual property portfolio and
large clinical safety database. Silence's clinical siRNA product pipeline is
one of the broadest in the industry. The Company possesses multiple proprietary
siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX
enables the broad functional delivery of siRNA molecules to targeted diseased
tissues and cells, while increasing their bioavailability and intracellular
uptake. The DACC delivery system allows functional delivery of siRNA molecules
selectively to the lung endothelium with a long duration of target mRNA and
protein knock-down. The DBTC delivery system enables functional delivery of
siRNA molecules selectively to liver cells including hepatocytes. Additionally,
the Company has a platform of novel siRNA molecules based around its AtuRNAi
chemical modification technology, which provides a number of advantages over
conventional siRNA molecules. Silence's unique RNAi assets also include
structural features for RNAi molecules and specific design rules for increased
potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation
in clinical development for systemic cancer indications and one of the most
clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027
incorporates two of the Company's technologies, AtuRNAi and AtuPLEX™. Silence
is currently conducting an open-label, single-centre, dose-escalation Phase I
study with Atu027 in patients with advanced solid tumors involving single, as
well as repeated, intravenous administration. Encouraging interim safety and
pharmacokinetic data were presented at the American Society of Clinical
Oncology Annual Meeting in June 2011. The study is expected to be completed in
the first half of 2012.

The Company's RNAi therapeutic platform has received key validation through
multiple partnerships with pharmaceutical companies including AstraZeneca,
Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively
pursuing the establishment of additional partnerships. Silence Therapeutics has
operations in both Berlin and London.

About miRagen Therapeutics (www.miragentherapeutics.com)

MiRagen Therapeutics, Inc., a pre-clinical stage biopharmaceutical company, was
founded in 2007 to develop innovative microRNA-based therapeutics for
cardiovascular and muscle disease. MicroRNAs are short, single-stranded RNA
molecules encoded in the genome that regulate gene expression and play a vital
role in influencing cardiovascular and muscle disease. Cardiovascular disease
is the leading cause of death globally and represents an enormous burden on
global healthcare systems. MiRagen combines world recognized leadership in
cardiovascular medicine with unprecedented in-house expertise in microRNA
biology and chemistry. In October 2011, miRagen and Les Laboratoires Servier, a
leading European pharmaceutical company, entered into a strategic alliance for
the research and development of microRNA-based therapeutics in cardiovascular
disease. For more information, please visit www.miragentherapeutics.com.

About MicroRNAs (miRNAs)

MicroRNAs have emerged as an important class of small RNAs encoded in the
genome. They act to control the expression of sets of genes and entire pathways
and are thus thought of as master regulators of gene expression. Recent studies
have demonstrated that microRNAs are associated with many disease processes.
Because they are single molecular entities that dictate the expression of
fundamental regulatory pathways, microRNAs represent potential drug targets for
controlling many biologic and disease processes.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to
risks, uncertainties and other factors. These risks and uncertainties could
cause actual results to differ materially from those referred to in the
forward-looking statements. All forward-looking statements are based on
information currently available to Silence Therapeutics and Silence
Therapeutics assumes no obligation to update any such forward-looking
statements.




END

Research and Development Collaboration Update

London, January 6, 2012 - Silence Therapeutics plc (AIM: SLN) ("Silence" or the
"Company"), a leading RNA interference (RNAi) therapeutics company, announces
the successful completion of its research work under the Research Collaboration
and Delivery Collaboration with its partner AstraZeneca and its biologics arm,
MedImmune. The first collaboration between Silence and AstraZeneca was
initiated in 2007 and was extended in 2010 and includes five research programs
on novel small interfering RNA (siRNA) therapeutic molecules for selected
targets. The second collaboration, focusing on the development of novel
approaches for the delivery of siRNA molecules, was established in 2008 and was
also extended in 2010.

Under the first collaboration, Silence and AstraZeneca successfully identified,
optimised and formulated novel siRNA molecules for selected targets and
executed certain studies for five research programs. Three of these programs
have been declared as "Accepted Programs" by AstraZeneca and can now be
advanced into pre-clinical development. AstraZeneca retains the global
development and commercial rights to these Accepted Programs. Silence will
retain all rights with respect to the two research programs which did not
become Accepted Programs. However, these two programs remain subject to a
two-year option with a first right of refusal in favour of AstraZeneca. In
addition, Silence acknowledges and agrees that AstraZeneca may continue to work
on these two programs solely for its own internal research purposes.

The second collaboration led to the development by Silence of a novel delivery
system for siRNA molecules, the DACC delivery system. Full rights to this
system have been retained by Silence and complement the Company's unique
AtuPLEX™ and DBTC RNAi delivery systems. The DACC delivery system allows
selective functional delivery of siRNA molecules to the lung endothelium with a
long duration of target mRNA and protein knock-down, compared to AtuPLEX™ which
is used for broad delivery to the vasculature of several organs and DBTC which
enables functional delivery of siRNA molecules selectively to liver cells
including hepatocytes.

Commenting on today's announcement, Thomas Christély, Chief Executive Officer
of Silence, said: "We are pleased by the progress that we have made in both
collaborations. In particular the delivery collaboration has enabled Silence to
make significant progress in developing a new technology that delivers RNAi to
target cells. The development of the lung focused RNAi delivery system DACC is
an important outcome of the delivery collaboration. The DACC delivery
technology is proprietary to Silence and can be applied to the other projects
that we are pursuing by ourselves and with partners."

David Blakey, Chief Scientist Oncology iMed and Chair of Oligonucleotide
Strategy Team, AstraZeneca, commented: "AstraZeneca and MedImmune remain
committed to the development of new technologies that have the potential to
create novel therapeutics. The collaboration with Silence Therapeutics has been
excellent and AstraZeneca and MedImmune will continue to evaluate the novel
siRNA molecules and the delivery technologies discovered under the
collaboration as part of its overall strategy to explore this important
therapeutic approach."

Ends


For further information, please contact:

Silence Therapeutics M:Communications

Thomas Christély/Max Herrmann Mary-Jane Elliott / Emma Thompson/
Claire Dickinson
+49 30 9489 2800/+44 20 7491 6520 +44 20 7920 2345 / +44 20 7920 2342
t.christely@silence-therapeutics.com silencetherapeutics@mcomgroup.com
m.herrmann@silence-therapeutics.com

Singer Capital Markets

Shaun Dobson/Claes Spång
+44 20 32057500
shaun.dobson@singercm.com
claes.spang@singercm.com



Notes for editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company
dedicated to the discovery, development and delivery of targeted, systemic RNA
interference (RNAi) therapeutics for the treatment of serious diseases. Silence
offers one of the most comprehensive short interfering RNA (siRNA) therapeutic
platforms available today based on a strong intellectual property portfolio and
large clinical safety database. Silence's clinical siRNA product pipeline is
one of the broadest in the industry. The Company possesses multiple proprietary
siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX
enables the broad functional delivery of siRNA molecules to targeted diseased
tissues and cells, while increasing their bioavailability and intracellular
uptake. The DACC delivery system allows functional delivery of siRNA molecules
selectively to the lung endothelium with a long duration of target mRNA and
protein knock-down. The DBTC delivery system enables functional delivery of
siRNA molecules selectively to liver cells including hepatocytes. Additionally,
the Company has a platform of novel siRNA molecules based around its AtuRNAi
chemical modification technology, which provides a number of advantages over
conventional siRNA molecules. Silence's unique RNAi assets also include
structural features for RNAi molecules and specific design rules for increased
potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation
in clinical development for systemic cancer indications and one of the most
clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027
incorporates two of the Company's technologies, AtuRNAi and AtuPLEX™. Silence
is currently conducting an open-label, single-centre, dose-escalation Phase I
study with Atu027 in patients with advanced solid tumors involving single, as
well as repeated, intravenous administration. Encouraging interim safety and
pharmacokinetic data were presented at the American Society of Clinical
Oncology Annual Meeting in June 2011. The study is expected to be completed in
the first half of 2012.

The Company's RNAi therapeutic platform has received key validation through
multiple partnerships with pharmaceutical companies including Dainippon
Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the
establishment of additional partnerships. Silence Therapeutics has operations
in both Berlin and London.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to
risks, uncertainties and other factors. These risks and uncertainties could
cause actual results to differ materially from those referred to in the
forward-looking statements. All forward-looking statements are based on
information currently available to Silence Therapeutics and Silence
Therapeutics assumes no obligation to update any such forward-looking
statements.




END